<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01469585</url>
  </required_header>
  <id_info>
    <org_study_id>UH DOXY RTRN</org_study_id>
    <nct_id>NCT01469585</nct_id>
  </id_info>
  <brief_title>Oral Contraceptives and Subantimicrobial Doxycycline: Effect on Endometrial Matrix Metalloproteinases</brief_title>
  <official_title>Oral Contraceptives and Subantimicrobial Doxycycline: Effect on Endometrial Matrix Metalloproteinases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Hawaii</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Charles Drew University of Medicine and Science</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Meharry Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Hawaii</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effects (good and bad) of subantimicrobial dose&#xD;
      doxycycline on the irregular bleeding women experience when taking continuous oral&#xD;
      contraceptive pills. This research is being done because currently, there is no effective&#xD;
      treatment for this condition. Findings from this study could help to decrease the side&#xD;
      effects of birth control pills and decrease unplanned pregnancies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Continuous oral contraceptive administration entails women taking hormonally active pills for&#xD;
      28 days without a seven day placebo week to avoid hormonal withdrawal bleeding.&#xD;
      Unfortunately, with continuous administration, timed, regular bleeding can be replace by&#xD;
      irregular, unscheduled bleeding, which often leads to dissatisfaction, discontinuation and&#xD;
      the possibility of unplanned pregnancy.&#xD;
&#xD;
      Matrix Metalloproteinases, a group of zinc-dependant proteases, are hypothesized to play a&#xD;
      role in endometrial degradation. The purpose of this study is to describe the expression of&#xD;
      Matrix Metalloproteinases in endometrial biopsy specimens collected 1) prior to initiating&#xD;
      oral contraceptives 2) while taking cyclic oral contraceptive 3) while taking continuous oral&#xD;
      contraceptives and 4) while taking continuous oral contraceptives along with&#xD;
      sub-antimicrobial doxycycline.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endometrial Matrix Metalloproteinase Expression by Gel Densitometry</measure>
    <time_frame>49 days</time_frame>
    <description>Baseline Matrix Metalloproteinase expression (activity level) will be determined on day 19-21 of cycle 1. During cycle 2, when women are taking the cyclic oral contraceptive, the endometrial biopsy will be performed between cycle day 19-21 (study day 47-49), prior to endometrial degradation and activity level will be noted. Of note, the outcome is MMP activity level, not a change in level.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Matrix Metalloproteinase Expression and Activity by Gel Densitometry</measure>
    <time_frame>84 days</time_frame>
    <description>Based on doxycycline's action as an Matrix Metalloproteinase inhibitor, it is hypothesized that Matrix Metalloproteinase expression and activity level will be decreased in women taking sub-antimicrobial doxycycline compared to women on continuous oral contraceptives only. The outcome is activity level (not a change in activity level)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Breakthrough Bleeding</condition>
  <arm_group>
    <arm_group_label>Sub-antimicrobial doxycycline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Women will take sub-antimicrobial doxycyline in addition to the continuous oral contraceptive pill.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuous Oral Contraceptive Pill</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Women will take only the continuous oral contraceptive.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline</intervention_name>
    <description>40 mg orally at the start of cycle 3 (study day 57) for 28 days.</description>
    <arm_group_label>Sub-antimicrobial doxycycline</arm_group_label>
    <other_name>Oracea</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women between the ages 18 and 45 who are ovulatory as demonstrated by a pre-treatment&#xD;
             Progesterone (P) greater than or equal to 3.0 ng/mL prior to oral contraceptive use&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women with any absolute contraindications to ethinyl estradiol and levonorgestrel;&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding&#xD;
&#xD;
          -  Use of oral contraceptives, patch, ring, intrauterine or implantable hormonal&#xD;
             contraception within 4-weeks;&#xD;
&#xD;
          -  Medroxyprogesterone acetate use within six months;&#xD;
&#xD;
          -  Current use of drugs that interfere with sex steroid metabolism.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bliss Kaneshiro, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Hawaii John A. Burns School of Medicine Department of Obstetrics and Gynecology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kapiolani Medical Center for Women and Children</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96826</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 8, 2011</study_first_submitted>
  <study_first_submitted_qc>November 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2011</study_first_posted>
  <results_first_submitted>May 22, 2018</results_first_submitted>
  <results_first_submitted_qc>November 23, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 17, 2020</results_first_posted>
  <last_update_submitted>November 23, 2020</last_update_submitted>
  <last_update_submitted_qc>November 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Hawaii</investigator_affiliation>
    <investigator_full_name>Bliss Kaneshiro</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>continuous oral contraceptives</keyword>
  <keyword>Matrix Metalloproteinase expression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metrorrhagia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sub-antimicrobial Doxycycline</title>
          <description>Women will take sub-antimicrobial doxycyline in addition to the continuous oral contraceptive pill.&#xD;
Doxycycline: 40 mg orally at the start of cycle 3 (study day 57) for 28 days.</description>
        </group>
        <group group_id="P2">
          <title>Continuous Oral Contraceptive Pill</title>
          <description>Women will take only the continuous oral contraceptive.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Active Comparator: Subantimicrobial Doxycycline</title>
          <description>Active comparator: Subantimicrobial doxycycline</description>
        </group>
        <group group_id="B2">
          <title>No Intervention: Continuous Oral Contraceptive Pill</title>
          <description>No intervention: Continuous oral contraceptive pill</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Endometrial Matrix Metalloproteinase Expression by Gel Densitometry</title>
        <description>Baseline Matrix Metalloproteinase expression (activity level) will be determined on day 19-21 of cycle 1. During cycle 2, when women are taking the cyclic oral contraceptive, the endometrial biopsy will be performed between cycle day 19-21 (study day 47-49), prior to endometrial degradation and activity level will be noted. Of note, the outcome is MMP activity level, not a change in level.</description>
        <time_frame>49 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sub-antimicrobial Doxycycline Group</title>
            <description>Sub-antimicrobial doxycycline group (controlled release subantimicrobial doxycycyline 40 mg once daily)</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Control (no medication)</description>
          </group>
        </group_list>
        <measure>
          <title>Endometrial Matrix Metalloproteinase Expression by Gel Densitometry</title>
          <description>Baseline Matrix Metalloproteinase expression (activity level) will be determined on day 19-21 of cycle 1. During cycle 2, when women are taking the cyclic oral contraceptive, the endometrial biopsy will be performed between cycle day 19-21 (study day 47-49), prior to endometrial degradation and activity level will be noted. Of note, the outcome is MMP activity level, not a change in level.</description>
          <units>relative expression</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" spread="0.41"/>
                    <measurement group_id="O2" value="2.49" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Matrix Metalloproteinase Expression and Activity by Gel Densitometry</title>
        <description>Based on doxycycline's action as an Matrix Metalloproteinase inhibitor, it is hypothesized that Matrix Metalloproteinase expression and activity level will be decreased in women taking sub-antimicrobial doxycycline compared to women on continuous oral contraceptives only. The outcome is activity level (not a change in activity level)</description>
        <time_frame>84 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sub-antimicrobial Doxycycline</title>
            <description>Women will take sub-antimicrobial doxycyline in addition to the continuous oral contraceptive pill.&#xD;
Doxycycline: 40 mg orally at the start of cycle 3 (study day 57) for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Continuous Oral Contraceptive Pill</title>
            <description>Women will take only the continuous oral contraceptive.</description>
          </group>
        </group_list>
        <measure>
          <title>Matrix Metalloproteinase Expression and Activity by Gel Densitometry</title>
          <description>Based on doxycycline's action as an Matrix Metalloproteinase inhibitor, it is hypothesized that Matrix Metalloproteinase expression and activity level will be decreased in women taking sub-antimicrobial doxycycline compared to women on continuous oral contraceptives only. The outcome is activity level (not a change in activity level)</description>
          <units>relative expression</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.52" spread="0.63"/>
                    <measurement group_id="O2" value="1.98" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Sub-antimicrobial Doxycycline</title>
          <description>Women will take sub-antimicrobial doxycyline in addition to the continuous oral contraceptive pill.&#xD;
Doxycycline: 40 mg orally at the start of cycle 3 (study day 57) for 28 days.</description>
        </group>
        <group group_id="E2">
          <title>Continuous Oral Contraceptive Pill</title>
          <description>Women will take only the continuous oral contraceptive.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Investigator</name_or_title>
      <organization>University of Hawaii</organization>
      <phone>808-203-6500</phone>
      <email>blissk@hawaii.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

